The efficient synthesis of some novel unsymmetrical 1,3-dialkylpyrimidines is described. N3-Alkylation of N1-substituted pyrimidine derivatives with various functionalized alkyl halides in the presence of catalytic amount of tetrabutylammonium bromide (TBAB) and Cs 2 CO 3 in MeCN affords the title compounds. The reactions proceed at room temperature and the products are obtained in good to excellent yields.
Introduction
In recent years, there has been a growing interest in the synthesis of bioactive compounds in organic chemistry.
1 One important class of these compounds is modified N-substituted nucleobases, including acyclic, 2 carboacyclic, 3 carbocyclic, 4 aza 5 and thionucleosides. 6 Some nucleoside derivatives possessing pyrimidine nucleobases have biological activities. The N1-β-hydroxy alkyl pyrimidine nucleobases seem to have attractive structures for investigation of carcinogenesis 3a and as accesses to therapeutic agents such as antiviral pyrimidine derivatives. Furthermore, the N1,N3-disubstituted pyrimidines are interesting as these compounds have required scaffold to consider as intercalating and alkylating agents. 7 The intercalating and alkylating agents nowadays have critical role in cancer chemotherapy. 7 Antiviral activity has been also reported for these compounds. 
Results and Discussion
In order to optimize the reaction conditions, the reaction of carboacyclic nucleoside 4a with 1-bromo-3-chloropropane was studied as a model reaction to provide compound 5a. At first, the influence of various bases in the presence of catalytic amounts of TBAB was examined to evaluate their capabilities (Table 1) . Higher yields and shorter reaction times were observed when Cs 2 CO 3 was used as base. Therefore, Cs 2 CO 3 was the base of choice for all reactions. Several reactions were carried out to understand the effect of other solvents beside MeCN on the results of reaction. A set of anhydrous solvents was examined for the previously described model reaction. The results are depicted in Table 2. As Table 2 indicates, the best results were obtained with MeCN.
To compare the efficiency of solution conditions versus solvent-free conditions, we have examined the model reaction under solvent-free conditions (microwave and thermal). The results are summarized in Table 3. As it is clear from Table 3 , the solution conditions are more efficient. To investigate the versatility as well as the capacity of our method, the reactions were examined with various N1-substituted nucleobases and alkyl halides ( Table 4) . As it is shown in Table 4 , the reactions proceeded efficiently and the desired N1,N3-dialkylated pyrimidines were obtained in good to excellent yields.
The effect of substituents (Me and F) on 5-position of 1-alkyl pyrimidines on N3-alkylation reaction was also studied. As Table 4 shows, the presence of a fluoro substituent had no significant effect on the reaction but the presence of a methyl substituent lowered the yields and increased the reaction times (Table 4 , entries 9-12). Compound 5d was obtained via reaction of carboacyclic nucleoside 4a with ethyl 3-bromopropanoate as well as ethyl acrylate. As Table  4 indicates, the reaction yield was remarkably higher when alkyl halide was used rather than α,β-unsaturated ester (Table 4 , entries 4 and 15). N3-Alkylation of carboacyclic nucleoside 4a with epoxide in the presence of TBAB and Cs 2 CO 3 in MeCN at room temperature was not successful (Table 4 , entry 16).
This method can be easily applied for N3-alkylation of 5'-protected uridine (classic nucleoside) (Table 4, entries 13-14). The 5'-DMT-uridine 6 reacted with 1-bromo-3-chloropropane and 2-(4-bromo-butyl)-isoindole-1,3-dione to afford compounds 7a and 7b in excellent yields and reasonable times (Table 4 , entries 13-14). The sugar residue has a little effect on N3-alkylation of uracil, nevertheless, it was expected that bulky sugar moiety to decrease the N3 tendency for alkylation. 
Conclusions
In summary, we have developed an efficient and simple method for N3-alkylation of N1-alkylpyrimine nucleobases in mild conditions. In this method, 1,3-dialkylpyrimidine nucleobases were synthesized as biologically interesting compounds in good to excellent yields.
Experimental Section
General Procedures. All chemicals were prepared from Merck or Fluka chemical companies.
Solvents were purified and dried according to reported methods and stored over molecular sieves 0.3 nm. 12 The progress of reaction was followed with TLC using silica gel SILG/UV 254 plates.
Silica gel 60, 0.063-0.200 mm (70-230 mesh ASTM) was used for column chromatography. IR spectra were run on a Shimadzu FTIR-8300 spectrophotometer. The 1 H NMR (250 MHz) and 13 C NMR (62.5 MHz) were run on a Bruker Avanced DPX-250, FT-NMR spectrometer. Mass spectra were recorded on a Shimadzu GC MS-QP 1000 EX apparatus. Microanalyses were performed on a Perkin-Elmer 240-B microanalyzer. N3-Alkylation of N1-substituted Pyrimidines with Carbon Electrophiles. A mixture of compounds consisting of 1-alkylpyrimidine nucleobase (0.010 mol), alkylating agent (0.015 mol), TBAB (0.322 g, 0.001 mol) and Cs 2 CO 3 (3.258 g, 0.010 mol) in anhydrous MeCN (30 mL) was stirred at room temperature for appropriate time (Table 3) . Then, the solids were filtered off and washed with MeCN (20 mL). The filtrate and washings were combined, the solvent was evaporated and the residual product was purified by column chromatography on silica gel with EtOAc/n-hexane (1/1). 3-(2,4-Dioxo-3,4-dihydro-2H-pyrimidine-1-yl)-propionic acid ethyl ester (4a). Colourless crystals; yield: 83%; mp 78-80 °C (Lit.
11a mp 78-80 °C).
3-(5-Methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidine-1-yl)-propionic acid ethyl ester (4b).
Colourless crystals; yield: 78%; mp 148-149 °C (Lit. 11a mp 148-149 °C). C, 53.84; H, 6.45; N, 8.97. Found: C, 53.63; H, 6.61; N. 8.80 . 43.9, 46.6, 61.5, 101.5, 123.9, 130.1, 144.1, 144.6, 147.7, 151.7, 163.1, 171.6 3-(3-Allyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) propionic acid ethyl ester (5g) . Pale yellow oil; isolated yield: 2.27 g (90%); IR (neat) ν max (cm , 57.59; H, 5.64; N, 11.19. Found: C, 57.87; H, 5.93; N. 11.50 . 3, 15.2, 30.3, 33.5, 38.4, 41.1, 45.5, 61.2, 109.1, 135.6, 149.2, 163.5, 171 4, 15.3, 33.9, 37.6, 42.1, 45.3, 61.3, 108.8, 134.2, 149.9, 162.9, 171.8; MS m/z (%) = 8.9 Hz, ), complex), complex), 7.88 (1H, d , J = 8.1 Hz, H 6 of uracil); 13 C NMR (CDCl 3 ): δ 30. 6, 39.1, 42.6, 55.2, 62.1, 70.1, 75.8, 83.7, 87.0, 90.9, 101.7, 113.3, 127.1, 128.2, 130.1, 135.1, 135.3, 138.2, 144.3, 151.5, 158.7, 162.7 9, 25.9, 37.6, 40.5, 62.2, 70.3, 75.8, 83.9, 86.9, 91.2, 101.6, 113.2, 123.2, 127.1, 128.0, 130.1, 132.0, 133.9, 135.1, 135.3, 137.9, 
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3-[3-(2-Hydroxy-ethyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) propionic acid ethyl ester (5e

